Urabrelimab

• CAT Number: I042130
• CAS Number: 2249722-58-3
• Purity: ≥95%

Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction[1].
Urabrelimab (SRF231) promotes macrophage-mediated phagocytic clearance of several hematologic primary tumor samples and cell lines in vitro. Urabrelimab increases phagocytosis of Raji tumor cell line targets with an EC50 of ~300 ng/mL[1].
Urabrelimab (SRF231) administration leads to profound tumor growth inhibition in models of multiple myeloma, diffuse large B cell lymphoma and Burkitt’s lymphoma as a single agent and in combination with opsonizing antibodies. In the Raji xenograft model, single agent therapy leads to 112% tumor growth inhibition[1].

Reference

[1]. Holland P M, et al. CD47 monoclonal antibody SRF231 is a potent inducer of macrophage-mediated tumor cell phagocytosis and reduces tumor burden in murine models of hematologic malignancies. 2016.